Chemomab Therapeutics Ltd. Financing Cash Flow
Chemomab Therapeutics Ltd. (CMMB) reported Financing Cash Flow of $7.16 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-23.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-03-23
- Chemomab Therapeutics Ltd. net cash provided by (used in) financing activities for the quarter ending 2023-06-30 was $1.37M, a 6118.18% increase year-over-year.
- Chemomab Therapeutics Ltd. net cash provided by (used in) financing activities for the quarter ending 2023-03-31 was $0.00.
- Chemomab Therapeutics Ltd. net cash provided by (used in) financing activities for the quarter ending 2022-12-31 was -$869.00K.
- Chemomab Therapeutics Ltd. net cash provided by (used in) financing activities for the quarter ending 2022-09-30 was $39.00K.
- Chemomab Therapeutics Ltd. net cash provided by (used in) financing activities for fiscal 2020 was $4.75M, a 82.16% decline from fiscal 2019.
- Chemomab Therapeutics Ltd. net cash provided by (used in) financing activities for fiscal 2019 was $26.62M, a 29.11% increase from fiscal 2018.
- Chemomab Therapeutics Ltd. net cash provided by (used in) financing activities for fiscal 2018 was $20.62M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 3 month as first filed | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 6 month as first filed | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 9 month as first filed | Net Cash Provided by (Used in) Financing Activities 12 month | Net Cash Provided by (Used in) Financing Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $7.16M 20-F · filed 2026-03-23 | |||||||
| 2025-06-30 | $1.31M 6-K · filed 2025-08-14 | |||||||
| 2024-12-31 | $9.87M 20-F · filed 2026-03-23 | |||||||
| 2024-06-30 | $132.00K 6-K · filed 2025-08-14 | |||||||
| 2023-12-31 | $3.50M 20-F · filed 2026-03-23 | |||||||
| 2023-06-30 | $1.37M derived: 6-K 6 month − 10-Q 3 month · filed 2024-08-21 | $1.37M 6-K · filed 2024-08-21 | $499.00K derived: sum of 3 quarters · filed 2025-04-04 | $538.00K derived: sum of 4 quarters · filed 2025-04-04 | ||||
| 2023-03-31 | $0.00 10-Q · filed 2023-05-11 | -$869.00K derived: sum of 2 quarters · filed 2025-04-04 | -$830.00K derived: sum of 3 quarters · filed 2025-04-04 | -$808.00K derived: sum of 4 quarters · filed 2025-04-04 | ||||
| 2022-12-31 | -$869.00K derived: 20-F 12 month − 10-Q 9 month · filed 2025-04-04 | -$830.00K derived: sum of 2 quarters · filed 2025-04-04 | -$808.00K derived: sum of 3 quarters · filed 2025-04-04 | -$808.00K 20-F · filed 2025-04-04 | ||||
| 2022-09-30 | $39.00K derived: 10-Q 9 month − 6-K 6 month · filed 2022-11-10 | $61.00K derived: sum of 2 quarters · filed 2023-08-14 | $61.00K 10-Q · filed 2022-11-10 | -$20.00K derived: sum of 4 quarters · filed 2024-03-28 | ||||
| 2022-06-30 | $22.00K derived: 6-K 6 month − 10-Q 3 month · filed 2023-08-14 | $22.00K 6-K · filed 2023-08-14 | -$59.00K derived: sum of 3 quarters · filed 2024-03-28 | -$131.00K derived: sum of 4 quarters · filed 2024-03-28 | ||||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-11 | -$81.00K derived: sum of 2 quarters · filed 2024-03-28 | -$153.00K derived: sum of 3 quarters · filed 2024-03-28 | $13.28M derived: sum of 4 quarters · filed 2024-03-28 | ||||
| 2021-12-31 | -$81.00K derived: 20-F 12 month − 10-Q 9 month · filed 2024-03-28 | -$153.00K derived: sum of 2 quarters · filed 2024-03-28 | $13.28M derived: sum of 3 quarters · filed 2024-03-28 | $61.07M 20-F · filed 2024-03-28 | ||||
| 2021-09-30 | -$72.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $13.36M derived: sum of 2 quarters · filed 2022-11-10 | $61.16M 10-Q · filed 2022-11-10 | $61.72M derived: sum of 4 quarters · filed 2022-11-10 | ||||
| 2021-06-30 | $13.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $61.23M 10-Q · filed 2022-08-12 | $61.79M derived: sum of 3 quarters · filed 2022-08-12 | $62.35M derived: sum of 4 quarters · filed 2022-08-12 | ||||
| 2021-03-31 | $47.80M 10-Q · filed 2022-05-12 | $48.36M derived: sum of 2 quarters · filed 2022-05-12 | $48.92M derived: sum of 3 quarters · filed 2022-05-12 | $52.05M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | $563.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $1.13M derived: sum of 2 quarters · filed 2022-03-30 | $4.25M derived: sum of 3 quarters · filed 2022-03-30 | $4.75M 10-K · filed 2022-03-30 | $297.00K 10-K · filed 2021-03-09 | |||
| 2020-09-30 | $562.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $3.69M derived: sum of 2 quarters · filed 2021-11-12 | $4.19M 10-Q · filed 2021-11-12 | $0.00 10-Q · filed 2020-11-16 | $4.19M derived: sum of 4 quarters · filed 2021-11-12 | |||
| 2020-06-30 | $3.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $3.63M 10-Q · filed 2021-08-13 | $0.00 10-Q · filed 2020-08-14 | $3.63M derived: sum of 3 quarters · filed 2021-08-13 | $3.63M derived: sum of 4 quarters · filed 2021-08-13 | |||
| 2020-03-31 | $500.00K 10-Q · filed 2021-05-13 | $0.00 10-Q · filed 2020-05-07 | $500.00K derived: sum of 2 quarters · filed 2021-05-13 | $500.00K derived: sum of 3 quarters · filed 2021-05-13 | -$698.00K derived: sum of 4 quarters · filed 2021-05-13 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $0.00 derived: sum of 2 quarters · filed 2021-03-09 | -$1.20M derived: sum of 3 quarters · filed 2021-03-09 | $26.62M 10-K · filed 2021-03-09 | ||||
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | -$1.20M derived: sum of 2 quarters · filed 2020-11-16 | $26.62M 10-Q · filed 2020-11-16 | |||||
| 2019-06-30 | -$1.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | $26.62M 10-Q · filed 2020-08-14 | ||||||
| 2019-03-31 | $27.82M 10-Q · filed 2020-05-07 | |||||||
| 2018-12-31 | $20.62M 10-K · filed 2020-03-17 |